2022

• • Mar.
  • HSG4112 Phase 2a study first dosing (obesity)

2021

• • Nov.
  • HSG4112 Phase 2a study IND effective (obesity)
• • Sep.
  • HSG4112 Phase 1 study completed

2019

• • Dec.
  • HSG4112 Phase 1 MAD study initiated
• • July
  • HSG4112 Phase 1 SAD study completed

2018

• • Sep.
  • HSG4112 Phase 1 SAD study initiated
• • Feb.
  • HSG4112 Phase 1 study IND effective

2017

• • Aug.
  • HSG4112 Preclinical study completed (obesity)
• • Mar.
  • Certificated as Venture Business and Company-affiliated Research Institute

2016

• • Apr.
  • Company renamed Glaceum
• • Jan.
  • HSG4112 Preclinical study initiated

2014

• • Dec.
  • IP registered
• • Apr.
  • Spin off from Erum Biotechnologies Inc.

2006~
20132006~2013.

• • Drug discovery